Skip to content
Peptigraph home

Tirzepatide Half-Life: How Long It Stays in Your System

How long Tirzepatide stays in the body, how that shapes dosing frequency, and what is known about drug testing.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP dual agonistUpdated
Half-life
approximately 5 days
subcutaneous, in people · FDA label (Mounjaro)
Dosing interval
Varies by study
as used in studies
WADA
Not listed
2026 Prohibited List
Detection window
Not found
None reported as of 2 Oct 2026

Tirzepatide half-life

A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray) and the species it was measured in, so we report each value with its route and source.

Tirzepatide half-life by route
RouteHalf-lifeMeasured inSource
subcutaneousapproximately 5 daysPeopleFDA label (Mounjaro)
subcutaneousapproximately 5-6 daysPeopleFDA label (Zepbound)
subcutaneous~5 days (population PK, 19 pooled studies)PeoplePMID 38356317

What half-life means

Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.

  • A long half-life lets a drug be dosed less often, for example once a week.
  • A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
  • Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.

What it means for dosing frequency

Dosing intervals used in published studies of Tirzepatide:

Changing the interval changes how much drug builds up between doses, so it is not a free choice.

Drug tests and sport

Not on the WADA Prohibited List

GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.

Anti-doping labs use tests built for specific substances. Whether a given test detects Tirzepatide, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026).

Two labels, two stated half-lives

The Mounjaro label gives a mean clearance of 0.061 L/h and a half-life of approximately 5 days, which it links to once-weekly dosing.[2]

The Zepbound label states 5-6 days and applies it to people with overweight or obesity and to people with obstructive sleep apnea and obesity.[3]

A population pharmacokinetic model built from pooled studies also gave a half-life of about 5 days. Its covariate analysis suggested that adjusting the dose regimen by demographics or subpopulation was unnecessary.[4]

Washout arithmetic at the two stated half-lives

At a 5-day half-life 5 half-lives is 25 days and at 6 days it is 30 days, each leaving about 3% of the drug under first-order elimination.

Calculated from 5-day half-life half life 5 days, after 1 half-lives (5 days) 50.0% of the original amount, after 3 half-lives (15 days) 12.5% of the original amount, after 5 half-lives (25 days) 3.1% of the original amount; 6-day half-life half life 6 days, after 1 half-lives (6 days) 50.0% of the original amount, after 3 half-lives (18 days) 12.5% of the original amount, after 5 half-lives (30 days) 3.1% of the original amount. Formula: remaining fraction = 0.5^(days / half-life)

Anti-doping status

The WADA list does not name tirzepatide, and the S0 catch-all excludes it because it is an approved medicine.[1]

Common questions

How long does Tirzepatide stay in your system?

Its reported half-life is approximately 5 days (subcutaneous); approximately 5-6 days (subcutaneous). Most of a dose is gone after about four to five half-lives.

What is the half-life of tirzepatide?

About 5 days on the Mounjaro label and 5-6 days on the Zepbound label.[3]

Is Tirzepatide on the WADA prohibited list?

No, it is not listed. GLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.

What is the half-life of Zepbound?

Zepbound's label says approximately 5-6 days, including in people with obstructive sleep apnea and obesity.[3]

What is the half-life of Mounjaro?

Mounjaro's label says approximately 5 days, with once-weekly dosing as the stated consequence.[2]

Is tirzepatide on the WADA list?

It is not named on the current list, and an approved drug falls outside the S0 catch-all clause quoted here.[1]

More on Tirzepatide

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  3. 3These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND. ZEPBOUND ® (tirzepatide) Injection, for subcutaneous uFDA label (Zepbound), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.CPT: pharmacometrics & systems pharmacology · 2024PMID 38356317Accessed 2 Oct 2026
  5. 5Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  6. 6Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
  7. 7Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2025PMID 39555826Accessed 2 Oct 2026
  8. 8Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.Reproductive biology and endocrinology : RB&E · 2025PMID 40604795Accessed 2 Oct 2026

Found an error? Report a correction.